Immune-Related Adverse Events (irAEs) – A Growing Challenge in Cancer Care: Management Strategies for Non-Oncology Nurses & Pharmacists
Released On
August 30, 2024
Expires On
February 28, 2025
Media Type
Internet
Completion Time
75 minutes
Specialty
Acute Care, Emergency Medicine, Education, Endocrinology, Gastroenterology, Hospitalist, Infectious Disease, Pharmacy, Rheumatology
Topic(s)
Pharmacology, Oncology, Immune-Related Adverse Events, irAEs
This activity is jointly provided by Postgraduate Healthcare Education, LLC (PHE) and Postgraduate Institute for Medicine (PIM).
This activity is supported by an independent educational grant from Merck & Co., Inc.
Credit Available
- Nurses — 1.25 Nursing Contact Hours
- Pharmacist — 1.25 hour (0.125 ceu) [PHARMACISTS: PLEASE GO TO POWERPAK at https://www.powerpak.com/course/preamble/125280 TO COMPLETE THIS LESSON AND CLAIM CREDIT.]
Target Audience
This activity is designed to meet the educational needs of nurses and pharmacists.
Program Overview
The goal of this educational activity is to equip non-oncology nurses and pharmacists with the skills needed to identify immune-related adverse events in patients treated with immune checkpoint inhibitors, apply guideline-recommended practices for the management of immune-related adverse events, counsel patients effectively, and refer patients back to their oncology providers when needed to improve patient quality of life and treatment outcomes.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify symptoms associated with the development of immune-related adverse events (irAEs) due to immune checkpoint inhibitors
- Describe guideline-recommended strategies to manage irAEs among patients who have received immunotherapy
- Formulate individualized irAE management strategies that involve care coordination with the oncology team and subspecialists
Faculty
Jordan P. McPherson, PharmD, MS, BCOP
Oncology Clinical Pharmacist, Melanoma and Non-Melanoma Skin Cancer
Huntsman Cancer Institute
Adjunct Assistant Professor
University of Utah College of Pharmacy
Salt Lake City, Utah
Dr. McPherson is an Oncology Clinical Pharmacist and Interim Clinical Manager for Oncology at Huntsman Cancer Institute at the University of Utah Health in Salt Lake City, Utah. Dr. McPherson specializes in the treatment of skin cancer using immunotherapy and other targeted therapies. Dr. McPherson’s research efforts are well published in peer-reviewed journals, including the Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, JCO Clinical Cancer Informatics, and Pharmacotherapy.
Marianne J. Davies DNP, ACNP, AOCNP, FAAN
Oncology Nurse Practitioner & Care Signature Manager
Medical Oncology
Yale New Haven Hospital at Yale Cancer Center
New Haven, CT
Dr. Davies is a Thoracic Oncology Nurse Practitioner at Smilow Cancer Hospital and Program Manager for Yale-New Haven Health in the Care Signature Pathway Development. She is an Assistant Professor at Yale University School of Nursing, Coordinating the Oncology Nurse Practitioner Concentration. Dr. Davies’ clinical specialty and publications are in the management of toxicities associated with immune checkpoint inhibitors and targeted therapies. She is a representative on the NCCN Management of Immunotherapy-Related Toxicity Guideline Panel and Chair of the Society of Immunotherapy Cancer: Advances in Cancer Immunotherapy Organizing Committee.
Accreditation Statements
Continuing Pharmacy Education
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-9999-24-062-H01-P
Credits: 1.25 hour (0.125 ceu)
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Postgraduate Healthcare Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosures of Conflicts of Interest
Dr. McPherson has disclosed that he has received funds for Contracted Research from Hitachi, LTD.
Dr. Davies has no actual or potential conflicts of interest in relation to this program.
The clinical reviewer, Megan May, PharmD, BCOP, has disclosed that she has served on the Amgen speakers bureau and as a consultant for Amgen, AstraZeneca, Genentech, Lilly and Pfizer.
Susanne Kwas, MSHF, BSN, RN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
The PIM planners and others have nothing to disclose.
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
Instructions for Participation and Credit
Pharmacists please go to https://www.powerpak.com/course/preamble/125280 to complete this lesson and claim credit.
Nurses, there are no fees for participating and receiving CE credit for this enduring activity. To receive CE credit participants must:
- Read the CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be immediately available for the participant.
Required Computer Hardware/Software
Please ensure the computer system you plan to use meets the following minimum requirements:
Operating System: Windows 98 or higher & Macintosh 2.2 or higherInternet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
Monitor Screen Resolution: 320 x 480 or higher
Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Postgraduate Institute for Medicine (PIM), or Merck & Co., Inc. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.
Contact Information
For CME questions please contact:
Nurses: [email protected]
Pharmacists: [email protected]